Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK Increases Stake in Theravance | Contract Pharma

What are you searching for?

Sign in
Breaking News

GSK Increases Stake in Theravance

Spends $213 million to boost ownership to 27%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline and Theravance, Inc. have entered into a stock purchase agreement, under which GSK will acquire 10 million shares of Theravance for a total of $212.9 million, increasing GSK’s ownership of Theravance from approximately 18.3% to approximately 26.8%. The transaction, subject to certain closing conditions, is scheduled for May 15, 2012.

In November 2002, the companies entered into a long-acting beta2 agonist (LABA) collaboration to develop and commercialize a once-daily LABA product candidate either as a single agent or in a combination medicine for the treatment of asthma and/or chronic obstructive pulmonary disease (COPD).

The inhaled corticosteroid (ICS)/ LABA combination, Relovair, has now completed Phase III development and GSK plans to submit regulatory applications for COPD and asthma in the U.S. and Europe.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters